Primary hepatocellular carcinoma (HCC) is one of the most common malignant tumors in China, and about 100,000 people die from this disease every year.The early symptoms of HCC are insidious, and patients are often in the middle to late stage when they are diagnosed. is the most widely used and its efficacy has been recognized. Although small hepatocellular carcinoma (<3 cm) has better treatment effect (all treatment methods are good), TACE is less effective in multifocal, giant type and combined with venous cancer thrombosis and adjacent organ invasion, because there are more and larger tumors and rich sources of blood supply arteries involved in tumors, so it is not easy to achieve complete embolization. After TACE treatment, because the local blood vessels are blocked causing hypoxia, the remaining, non-necrotic tumor tissues will produce a series of factors that promote blood vessel growth (VEGF is the most common), so that new blood vessels will be produced to form collateral circulation in order to make the tumor continue to grow. In fact, sorafenib was initially used only as a first-line drug for the treatment of advanced renal cell carcinoma, which has a rich blood supply and is insensitive to radiotherapy, and there is basically nothing particularly effective if it cannot be surgically removed. Sorafenib, an inhibitor of multiple kinases, has the effect of blocking tumor cell proliferation and inhibiting neovascularization, and has been proven to have significant efficacy in renal cell carcinoma. Based on the fact that the occurrence and development of HCC is the combined result of multiple etiologies, multiple risk factors and the involvement of multiple signaling pathways, and that the blood supply is particularly rich, medical professionals considered that sorafenib should also be effective against HCC, and reported internationally that a 2-group randomized controlled study using doxorubicin alone for hepatocellular carcinoma resulted in about 50% longer median survival time than the placebo group. Accordingly, the American Society of Clinical Oncology (ASCO) recommended sorafenib as a first-line treatment for advanced HCC, and China also approved it as a treatment for advanced HCC. In terms of mechanism of action, TACE combined with sorafenib should be more effective. We have done 12 patients (including 3 patients with recurrence after liver transplantation) with an objective efficiency of 33.1%, including 1 case with recurrence after liver transplantation and then surgery and recurrence with lung and bone metastases, who has been taking sorafenib for 8 months after liver and bone metastases intervention. He has been taking sorafenib for 8 months after intervention for liver and bone metastases. In addition to the high price of sorafenib, the most criticized side effects are more frequent, with an incidence of more than 80% in China, especially diarrhea, skin damage, and weakness, but most of them can be tolerated. In addition, compared with European and American patients, there may be physical differences and our patients may be able to reduce the daily dose appropriately to reduce side effects, but there is not much experience yet. In conclusion, the combination of TACE with sorafenib can superimpose the effects of the two to achieve a 1 + 1 > 2 effect, which is especially suitable for larger patients with HCC who have a particularly rich blood supply prone to form collateral circulation and with lung and bone metastases.